• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Biomedical and Pharmaceutical Sciences
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 8 (2025)
Volume Volume 7 (2024)
Volume Volume 6 (2023)
Volume Volume 5 (2022)
Volume Volume 4 (2021)
Volume Volume 3 (2020)
Volume Volume 2 (2019)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 1 (2018)
Saber, M., Sarhan, H., Fouad, Y., Mohammed, E. (2019). Overview on Hepatic Encephalopathy. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2(3), 111-115. doi: 10.21608/jabps.2019.10642.1038
Mona Ali Saber; Hatem Sarhan; Yasser Mahrous Fouad; El-Shaimaa Ahmed Mohammed. "Overview on Hepatic Encephalopathy". Journal of Advanced Biomedical and Pharmaceutical Sciences, 2, 3, 2019, 111-115. doi: 10.21608/jabps.2019.10642.1038
Saber, M., Sarhan, H., Fouad, Y., Mohammed, E. (2019). 'Overview on Hepatic Encephalopathy', Journal of Advanced Biomedical and Pharmaceutical Sciences, 2(3), pp. 111-115. doi: 10.21608/jabps.2019.10642.1038
Saber, M., Sarhan, H., Fouad, Y., Mohammed, E. Overview on Hepatic Encephalopathy. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2019; 2(3): 111-115. doi: 10.21608/jabps.2019.10642.1038

Overview on Hepatic Encephalopathy

Article 4, Volume 2, Issue 3, July 2019, Page 111-115  XML PDF (675.09 K)
Document Type: Review Articles
DOI: 10.21608/jabps.2019.10642.1038
View on SCiNiTO View on SCiNiTO
Authors
Mona Ali Saber email 1; Hatem Sarhan2; Yasser Mahrous Fouad3; El-Shaimaa Ahmed Mohammed3
1Department of Clinical pharmacy, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt
2Department of Pharmaceutics, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt
3Department of Endemic Medicine, Faculty of Medicine, Minia University, 61519 Minia, Egypt
Abstract
Hepatic encephalopathy (HE) has appeared in the last years as serious, life threatening and debilitating complication of both persistent and episodic liver diseases. This review explores HE definition, pathogenesis, diagnosis and available treatment options. Overt HE is a major cause for hospitalization, readmission and even death in cirrhotic patients, while covert HE can affect negatively on patient quality of life, ability of driving and survival. Clinical manifestations of HE include cognitive function impairment and deteriorated psychometric motor functions. Diagnostic options for HE are varied and depend on the impairment degree and the acuity of clinical presentations of HE. Pathogenesis of HE is sophisticated and depends on several factors, however, ammonia is considered to play a critical role in HE pathophysiology. Management options of HE include controlling of precipitating factors, medical treatment and liver transplantation. Standard medical treatment of HE comprises non-absorbable disaccharides as lactulose and some antibiotics as rifaximin. Newer drugs that act on serum ammonia level have a vital role in management of HE, such as l-ornithine-l-aspartate, sodium phenylbutyrate and sodium benzoate.
Keywords
hepatic encephalopathy; ammonia; hyperammonemia
Main Subjects
Clinical Pharmacy
Statistics
Article View: 479
PDF Download: 1,042
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.